Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Chemours Co-The Market Cap
Based on ratings from 9 stock analysts, the Chemours Co-The stock price is expected to increase by 9.37% in 12 months. This is calculated by using the average 12-month stock price forecast for Chemours Co-The. The lowest target is $18 and the highest is $32. Please note analyst price targets are not guaranteed and could be missed completely.
Chemours Co-The has a total of 9 Wall St Analyst ratings. There are 3 buy ratings, 6 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Chemours Co-The will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Arun Viswanathan RBC Capital | Outperform | $25 | Maintains | Nov 6, 2024 |
| Michael Leithead Barclays | Equal-Weight | $23 | Maintains | Nov 5, 2024 |
| Vincent Andrews Morgan Stanley | Equal-Weight | $25 | Maintains | Nov 5, 2024 |
| Arun Viswanathan RBC Capital | Outperform | $28 | Maintains | Oct 11, 2024 |
| John McNulty BMO Capital | Outperform | $32 | Maintains | Oct 7, 2024 |
| Michael Leithead Barclays | Equal-Weight | $21 | Maintains | Sep 25, 2024 |
| Duffy Fischer Goldman Sachs | Neutral | $23 | Maintains | Sep 3, 2024 |
| Jeffrey Zekauskas JP Morgan | Neutral | $18 | Maintains | Aug 6, 2024 |
| Michael Leithead Barclays | Equal-Weight | $22 | Maintains | Aug 6, 2024 |
| John McNulty BMO Capital | Outperform | $30 | Maintains | Aug 6, 2024 |
| Joshua Spector UBS | Buy | $28 | Maintains | Aug 6, 2024 |
| Joshua Spector UBS | Buy | $30 | Upgrade | Jul 9, 2024 |
| John Roberts Mizuho | Neutral | $25 | Initiates | Jun 7, 2024 |
| John McNulty BMO Capital | Outperform | $34 | Upgrade | Apr 9, 2024 |
| Joshua Spector UBS | Neutral | $28 | Maintains | Apr 2, 2024 |
| Michael Leithead Barclays | Equal-Weight | $30 | Maintains | Apr 2, 2024 |
| Joshua Spector UBS | Neutral | $21 | Downgrade | Mar 5, 2024 |
| John McNulty BMO Capital | Underperform | $19 | Downgrade | Mar 1, 2024 |
| John McNulty BMO Capital | Underperform | $19 | Downgrade | Feb 29, 2024 |
| Arun Viswanathan RBC Capital | Outperform | $40 | Upgrade | Dec 1, 2023 |
When did it IPO
2015
Staff Count
6,200
Country
United States
Sector/Industry
Basic Materials/Specialty Chemicals
CEO
Ms. Denise M. Dignam
Market Cap
$3.26B
In 2023, CC generated $6.03B in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Chemours Company completed a private offering of $600 million in 8.000% senior unsecured notes, maturing in 2033.
Why It Matters - The Chemours Company's $600 million bond offering at 8% indicates strong capital needs and might impact leverage and cash flow, influencing credit ratings and stock performance.
Thu, 21 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Chemours Company has underperformed in 2024 with a 36% YTD decline. Despite seasonal challenges, its Thermal & Specialized Solutions division is driving growth, supported by regulatory tailwinds.
Why It Matters - Chemours' underperformance raises concerns, but growth in its profitable division and regulatory support may signal a potential turnaround, influencing investment decisions.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Chemours Company is conducting a private offering of $600 million in senior notes due in 2033.
Why It Matters - The Chemours Company's $600 million senior notes offering signals its capital-raising efforts, impacting debt levels, liquidity, and future growth potential, influencing investor sentiment.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Chemours Company has priced a private offering of $600 million in 8.000% senior notes maturing in 2033.
Why It Matters - Chemours’ $600M senior notes offering indicates strong financing strategy, potentially impacting liquidity and debt levels, influencing credit ratings and investment appeal.
Mon, 11 Nov 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Investors often seek dividend-yielding stocks during market turbulence, focusing on companies with strong free cash flows and high dividend payouts.
Why It Matters - Dividend-yielding stocks attract investors during market volatility, offering stability and income through high payouts, reflecting strong cash flows and potentially reducing portfolio risk.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Chemours (NYSE: CC) held its Q3 2024 earnings call on November 4, 2024, featuring CEO Denise Dignam and CFO Shane Hostetter, with participation from major financial analysts.
Why It Matters - The Chemours Q3 2024 earnings call provides insights into the company's financial health and future outlook, influencing stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
